© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#IAS 2017
Click Here for More Conferences
Click Here for IAS Online
HIV: The Basics

Good Long-Term Results for Mid-Stage HIV Vaccine Study

The vaccine in the APPROACH study, which led to the Imbokodo and forthcoming Mosaico trails, prompted a robust immune response.

Mixed-HIV-Status Gay Couples Employ Multiple Risk-Reduction Strategies

Researchers broke down the various strategies that the gay men in the Opposites Attract study used to prevent HIV transmission.

Gilead’s Biktarvy Is as Effective as Tivicay Plus Descovy

Biktarvy has a lower rate of adverse health events, according to 96-week data.

Switching to Janssen’s Symtuza Is Safe and Effective Up to 96 Weeks

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Switching to Merck’s New HIV Regimen Delstrigo Is Safe and Effective

According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.

ViiV’s 2-Drug Regimen Is on Par With a 3-Drug Combo

Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.

Merck’s Experimental HIV Drug Doravirine Posts Promising 96-Week Results

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

HIV Vax in Advanced Trial Posts Promising 2-Year Results

Ninety-six–week data from the Phase I/IIa trial showed the mosaic vaccine was safe and offered a broad and durable immune response.

Undetectable Meant Zero HIV Transmissions After 89,000 Condomless Sex Acts

The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.

Early HIV Vaccine Study Raises Hopes for Ongoing Larger Trial

Published results have updated preliminary findings presented at a previous conference.

Merck Applies to FDA for Approval of New HIV Med Doravirine

The new drug application is for doravirine as both an individual tablet and part of a combination tablet.

Question Motives

HIV researcher David Alain Wohl, MD, urges AIDS activists to be a vanguard against indifference, overreach and shortsightedness.
ACT UP New York members at the 2017 LGBT Pride March

Around the Edges

Writer Anna Forbes responds to an open letter by HIV researcher David Alain Wohl, MD, that urges AIDS activists to do more.

Gilead’s New Bictegravir-Based HIV Combo Pill Performs Well

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
Michael Weinstein

Unpacking Michael Weinstein’s Latest PrEP Denialism

The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.

IAS 2017

The social media buzz on the annual HIV science conference.
Advertisement
Newsfeed
Science News
Features
Opinions